Trial Profile
A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Berzosertib (Primary) ; Cisplatin (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 13 Mar 2024 Planned End Date changed from 31 Dec 2023 to 12 Mar 2025.
- 06 Dec 2023 Planned End Date changed from 12 Sep 2023 to 31 Dec 2023.
- 06 Dec 2023 Planned primary completion date changed from 12 Sep 2023 to 31 Dec 2023.